SynAct Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:8F8 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
21 Mar 24	Buy€8,659	Thomas Boesen	Individual		14,250	€0.61
21 Mar 24	Sell€12,760	Thomas Boesen	Individual		21,000	€0.61

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.1%.

Top 18 shareholders own 48.93% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.6%	NBCD A/S	3,962,790	€3.9m	0%	no data
9.08%	Heights Capital Management, Inc.	3,750,000	€3.7m	0%	1.28%
5.46%	Thomas Ringberg	2,252,969	€2.2m	0%	no data
5.23%	TJ Biotech Invest ApS	2,161,225	€2.1m	0%	no data
4.11%	Nordnet AB (publ), Asset Management Arm	1,698,777	€1.7m	0%	0.22%
3.63%	Ryan Quinn	1,500,000	€1.5m	0%	no data
3.46%	Quantass Invest Aps	1,428,558	€1.4m	0%	no data
2.81%	Goodwind Holding GmbH	1,161,777	€1.1m	0%	no data
1.89%	Handelsbanken Asset Management	781,198	€769.2k	0%	no data
1.67%	Bioinvest Sverige Ab	688,670	€678.1k	0%	no data
0.81%	Thomas Jonassen	332,864	€327.8k	0%	no data
0.76%	SEB Investment Management AB	311,951	€307.2k	0%	no data
0.22%	FCG Fonder AB	91,386	€90.0k	0%	0.01%
0.089%	Skandia Fonder AB	36,871	€36.3k	0%	no data
0.045%	Thomas Boesen	18,604	€18.3k	0%	no data
0.033%	Jeppe Ovlesen	13,825	€13.6k	0%	no data
0.03%	Storebrand Fonder AB,	12,469	€12.3k	0%	no data
0.0022%	State Street Global Advisors, Inc.	923	€910.9	12.7%	no data